A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial

Table 3 Results of the base-case analysis

Treatment	Total cost, $	Overall LYs	Overall QALYs	ICER, $
Treatment	Total cost, $	Overall LYs	Overall QALYs	per LY	per QALY
Overall population
Serplulimab plus CF	7,241	0.87	0.44	11,975	23,657
CF	4,078	0.60	0.30	-	-
Patients with PD-L1 expression level of 1 ≤ CPS < 10
Serplulimab plus CF	6,333	0.76	0.38	11,367	23,982
CF	3,915	0.55	0.28	-	-
Patients with PD-L1 CPS ≥ 10
Serplulimab plus CF	8,286	0.97	0.49	13,672	25,134
CF	4,437	0.68	0.34	-	-

Abbreviation: LYs, life-years; QALYs, quality-adjusted life-years; ICER, incremental cost-effectiveness ratio; CF, cisplatin and 5-fluorouracil; PD-L1, programmed death ligand 1; CPS, combined positive score

ISSN: 1478-7547